Synopsis:- Speciality Medicines Limited, listed on BSE-SME just 23 days ago, has announced a commercial distribution arrangement with an unnamed international entity for pharmaceutical finished products valued at approx Rs. 14 crore (USD 1.5 million).
Shares of a recently listed specialty pharmaceutical exporter came into focus on Wednesday after the company disclosed, a commercial arrangement with an international entity for the marketing and sale of its pharmaceutical finished product portfolio. The announcement, filed directly by the Chairman and Managing Director, follows the company’s BSE-SME listing on March 30, 2026 making this the first material order disclosure since its IPO, timed just 23 days after listing.
With a market capitalisation of Rs. 262.52 crore, the shares of Speciality Medicines Limited were trading at Rs. 298.8 per share, up 5 percent from its previous close of Rs.284.6.
The disclosure states that the company has finalised a commercial arrangement with an international entity that imports and distributes pharmaceutical finished products. Under the arrangement, this unnamed entity has agreed to distribute, market, and sell the company’s products at an approximate value of USD 1.5 million, described in the filing as roughly Rs. 14 crore. Both parties have explicitly confirmed there is no promoter-group interest or related-party angle.
Beyond these parameters, the filing is light on specifics. No country of operation is named for the buyer, no product categories or SKUs are listed, no delivery schedule is disclosed, and no payment terms are mentioned.
At approximately Rs. 14 crore, the arrangement is worth about 24 percent of the company’s FY25 standalone revenue of Rs. 58.27 crore; a meaningful quantum if it translates into actual offtake. The company’s revenue trajectory, however, carries a note of caution: sales fell from Rs. 40 crore in FY22 to Rs. 23 crore in FY23 before recovering to Rs. 27 crore in FY24 and then jumping to Rs. 58 crore in FY25. The FY25 jump is the primary driver behind the 112 percent TTM sales growth, and its sustainability is untested.
More persistently, the company has generated negative operating cash flows in three of its four reported years (minus Rs. 4.21 crore in FY23, minus Rs. 4.80 crore in FY24, and minus Rs. 5.79 crore in FY25). Free cash flow has been negative in all four years. The cash conversion cycle stood at 202 days in FY25 reflecting inventory days of 150 and a working capital position that absorbs capital well ahead of collections.
Specialty pharmaceutical trading inherently carries high working capital intensity, particularly for oncology, immunology, and rare disease products where procurement lead times are long and inventory values are high. But three consecutive years of operational cash burn, funded by increasing borrowings (Rs. 5.05 crore in FY25 versus Rs. 1.18 crore in FY22) and IPO proceeds, is a structural feature that a distribution arrangement alone will not resolve unless collections on international sales arrive promptly. Debtor days, notably, improved sharply from 142 in FY24 to 60 in FY25.
Business Overview
Speciality Medicines Limited, incorporated in 2021, is engaged in the marketing and distribution of specialty pharmaceutical formulations across therapeutic areas including oncology, immunology, neurology, and rare diseases. The company operates from Mumbai with its registered office in Ahmedabad.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
